Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. [L'application topique de médicaments anti-fibrinolytiques pour la chirurgie cardiaque avec circulation extra-corporelle : analyse méthodique et méta-analyse.] [English, French abstract] (abre nova janela)

Abrishami A, Chung F, Wong J.

Fonte‎: Can J Anaesth 2009;56(3):202-12.

Indexado‎: PubMed 19247741

DOI‎: 10.1007/s12630-008-9038-x

https://www.ncbi.nlm.nih.gov/pubmed/19247741 (abre nova janela)

Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation. (abre nova janela)

Dell'Amore A, Caroli G, Nizar A, Cassanelli N, Luciano G, Greco D, Dolci G, Bini A, Stella F.

Fonte‎: Heart Lung Circ 2012;21(11):706-10.

Indexado‎: PubMed 22842057

DOI‎: 10.1016/j.hlc.2012.06.016

https://www.ncbi.nlm.nih.gov/pubmed/22842057 (abre nova janela)

Can local application of tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. (abre nova janela)

Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L.

Fonte‎: J Cardiothorac Surg 2009;4:25.

Indexado‎: PubMed 19538741

DOI‎: 10.1186/1749-8090-4-25

https://www.ncbi.nlm.nih.gov/pubmed/19538741 (abre nova janela)

Current status of pharmacologic therapies in patient blood management. (abre nova janela)

Goodnough LT, Shander A.

Fonte‎: Anesth Analg 2013;116(1):15-34.

Indexado‎: PubMed 23223098

DOI‎: 10.1213/ANE.0b013e318273f4ae

https://www.ncbi.nlm.nih.gov/pubmed/23223098 (abre nova janela)

The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. (abre nova janela)

Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham JM, Wall MH, Butterworth JF.

Fonte‎: Anesth Analg 2009;109(1):15-24.

Indexado‎: PubMed 19535691

DOI‎: 10.1213/ane.0b013e3181a40b5d

https://www.ncbi.nlm.nih.gov/pubmed/19535691 (abre nova janela)

Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. (abre nova janela)

Howell N, Senanayake E, Freemantle N, Pagano D.

Fonte‎: J Thorac Cardiovasc Surg 2013;145(1):234-40.

Indexado‎: PubMed 22889481

DOI‎: 10.1016/j.jtcvs.2012.07.018

https://www.ncbi.nlm.nih.gov/pubmed/22889481 (abre nova janela)

The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. (abre nova janela)

Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS.

Fonte‎: Anesth Analg 2010;110(1):21-9.

Indexado‎: PubMed 19910626

DOI‎: 10.1213/ANE.0b013e3181c0ea6d

https://www.ncbi.nlm.nih.gov/pubmed/19910626 (abre nova janela)

Comparative evaluation of the effects of tranexamic acid and low-dose aprotinin on post-valvular heart surgery bleeding and allogenic transfusion. (abre nova janela)

Mansouri M, Attary M, Bagheri K, Massoumi G, Ghavami B.

Fonte‎: Interact Cardiovasc Thorac Surg 2012;15(1):23-7.

Indexado‎: PubMed 22514257

DOI‎: 10.1093/icvts/ivs114

https://www.ncbi.nlm.nih.gov/pubmed/22514257 (abre nova janela)

A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting. (abre nova janela)

Murphy GJ, Mango E, Lucchetti V, Battaglia F, Catapano D, Rogers CA, Angelini GD.

Fonte‎: J Thorac Cardiovasc Surg 2006;132(3):475-80, 480.e1-8.

Indexado‎: PubMed 16935098

DOI‎: 10.1016/j.jtcvs.2006.01.064

https://www.ncbi.nlm.nih.gov/pubmed/16935098 (abre nova janela)

Tranexamic acid in patients undergoing coronary-artery surgery. (abre nova janela)

Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network

Fonte‎: N Engl J Med 2017;376(2):136-48.

Indexado‎: PubMed 27774838

DOI‎: 10.1056/NEJMoa1606424

http://www.ncbi.nlm.nih.gov/pubmed/27774838 (abre nova janela)

Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass. (abre nova janela)

Nurözler F, Kutlu T, Küçük G.

Fonte‎: Asian Cardiovasc Thorac Ann 2008;16(6):483-7.

Indexado‎: PubMed 18984759

DOI‎: 10.1177/021849230801600611

https://www.ncbi.nlm.nih.gov/pubmed/18984759 (abre nova janela)

Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. (abre nova janela)

Shi J, Ji H, Ren F, Wang G, Xu M, Xue Y, Chen M, Qi J, Li L.

Fonte‎: JAMA Surg 2013;148(6):538-47.

Indexado‎: PubMed 23426385

DOI‎: 10.1001/jamasurg.2013.1560

https://www.ncbi.nlm.nih.gov/pubmed/23426385 (abre nova janela)

Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: The OPTIMAL randomized clinical trial. (abre nova janela)

Shi J, Zhou C, Pan W, Sun H, Liu S, Feng W, Wang W, Cheng Z, Wang Y, Zheng Z

Fonte‎: JAMA. 2022;328(4):336-47.

Indexado‎: PubMed 35881121

DOI‎:  10.1001/jama.2022.10725

https://pubmed.ncbi.nlm.nih.gov/35881121/ (abre nova janela)

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study. (abre nova janela)

Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, Liu M, Chen L, Li L.

Fonte‎: Anesth Analg 2012;115(2):239-43.

Indexado‎: PubMed 21737704

DOI‎: 10.1213/ANE.0b013e3182264a11

https://www.ncbi.nlm.nih.gov/pubmed/21737704 (abre nova janela)

Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. (abre nova janela)

Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S.

Fonte‎: Ann Thorac Surg 2010;89(5):1489-95.

Indexado‎: PubMed 20417766

DOI‎: 10.1016/j.athoracsur.2010.02.006

https://www.ncbi.nlm.nih.gov/pubmed/20417766 (abre nova janela)

Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. (abre nova janela)

Øvrum E, Tangen G, Tølløfsrud S, Ringdal MA, Øystese R, Istad R.

Fonte‎: Interact Cardiovasc Thorac Surg 2010;10(4):545-8.

Indexado‎: PubMed 20067988

DOI‎: 10.1510/icvts.2009.226613

https://www.ncbi.nlm.nih.gov/pubmed/20067988 (abre nova janela)

Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? (abre nova janela)

Ballen J, Raabe M, Muirhead B.

Fonte‎: Can J Anaesth 2006;53(4):353-6.

Indexado‎: PubMed 16575032

DOI‎: 10.1007/BF03022498

https://www.ncbi.nlm.nih.gov/pubmed/16575032 (abre nova janela)

Use of recombinant activated factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. (abre nova janela)

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Fonte‎: Transfusion 2013;53(4):798-804.

Indexado‎: PubMed 22845023

DOI‎: 10.1111/j.1537-2995.2012.03801.x

https://www.ncbi.nlm.nih.gov/pubmed/22845023 (abre nova janela)

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. (abre nova janela)

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Fonte‎: Ann Thorac Surg 2008;85(3):836-44.

Indexado‎: PubMed 18291152

DOI‎: 10.1016/j.athoracsur.2007.06.076

https://www.ncbi.nlm.nih.gov/pubmed/18291152 (abre nova janela)

Repeat cardiac surgery in a Jehovah's Witness patient with thrombocytopenia. (abre nova janela)

Elmistekawy E, Lapierre H, Bourke M, Dennie C, Labinaz M, Ruel M.

Fonte‎: Can J Cardiol 2011;27(6):869.e7-8.

Indexado‎: PubMed 21983113

DOI‎: 10.1016/j.cjca.2011.07.632

https://www.ncbi.nlm.nih.gov/pubmed/21983113 (abre nova janela)

Off-label use of recombinant activated factor VII for cardiac surgical bleeding. (abre nova janela)

Flynn BC, Steiner ME, Mazzeffi M

Fonte‎: Anesthesiology. 2023 1;139(2):197-210.

Indexado‎: PubMed 37155359

DOI‎: 10.1097/ALN.0000000000004569

https://pubmed.ncbi.nlm.nih.gov/37155359/ (abre nova janela)

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. (abre nova janela)

Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA.

Fonte‎: Circulation 2009;120(1):21-7.

Indexado‎: PubMed 19546387

DOI‎: 10.1161/CIRCULATIONAHA.108.834275

https://www.ncbi.nlm.nih.gov/pubmed/19546387 (abre nova janela)

Intraoperative use of recombinant activated factor VII during complex aortic surgery. (abre nova janela)

Goksedef D, Panagopoulos G, Nassiri N, Levine RL, Hountis PG, Plestis KA.

Fonte‎: J Thorac Cardiovasc Surg 2012;143(5):1198-204.

Indexado‎: PubMed 22285329

DOI‎: 10.1016/j.jtcvs.2012.01.004

https://www.ncbi.nlm.nih.gov/pubmed/22285329 (abre nova janela)

Off-label use of recombinant human factor VIIa. (abre nova janela)

Goodnough LT, Levy JH.

Fonte‎: Ann Thorac Surg 2014;98(2):393-5.

Indexado‎: PubMed 25087781

DOI‎: 10.1016/j.athoracsur.2014.06.007

https://www.ncbi.nlm.nih.gov/pubmed/25087781 (abre nova janela)

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). (abre nova janela)

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Fonte‎: Eur J Cardiothorac Surg 2011;40(6):1320-7.

Indexado‎: PubMed 21550261

DOI‎: 10.1016/j.ejcts.2011.03.032

https://www.ncbi.nlm.nih.gov/pubmed/21550261 (abre nova janela)

Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. (abre nova janela)

Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, Cheng D, Heinrich L, Kent B, Lee TW, MacAdams C, Mazer CD, Muirhead B, Rochon AG, Rubens FD, Sawchuk C, Wang S, Waters T, Wong BI, Yau TM.

Fonte‎: Circulation 2008;118(4):331-8.

Indexado‎: PubMed 18606914

DOI‎: 10.1161/CIRCULATIONAHA.108.764308

https://www.ncbi.nlm.nih.gov/pubmed/18606914 (abre nova janela)

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. (abre nova janela)

Končar IB, Davidović LB, Savić N, Sinđelić RB, Ilić N, Dragas M, Markovic M, Kostic D.

Fonte‎: J Vasc Surg 2011;53(4):1032-7.

Indexado‎: PubMed 21215579

DOI‎: 10.1016/j.jvs.2010.07.075

https://www.ncbi.nlm.nih.gov/pubmed/21215579 (abre nova janela)

Use of activated recombinant factor VII in severe bleeding—evidence for efficacy and safety in trauma, postpartum hemorrhage, cardiac surgery, and gastrointestinal bleeding. (abre nova janela)

Lau P, Ong V, Tan WT, Koh PL, Hartman M.

Fonte‎: Transfus Med Hemother 2012;39(2):139-50.

Indexado‎: PubMed 22670132

DOI‎: 10.1159/000338034

https://www.ncbi.nlm.nih.gov/pubmed/22670132 (abre nova janela)

Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection. (abre nova janela)

Lehr EJ, Alford TJ, Wang SH.

Fonte‎: Heart Surg Forum 2010;13(5):E275-9.

Indexado‎: PubMed 20961825

DOI‎: 10.1532/HSF98.20101027

https://www.ncbi.nlm.nih.gov/pubmed/20961825 (abre nova janela)

Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. (abre nova janela)

Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG.

Fonte‎: J Cardiothorac Vasc Anesth 2009;23(1):28-33.

Indexado‎: PubMed 18948033

DOI‎: 10.1053/j.jvca.2008.08.003

https://www.ncbi.nlm.nih.gov/pubmed/18948033 (abre nova janela)

Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. (abre nova janela)

Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM.

Fonte‎: Drugs R D 2015;15(2):187-94.

Indexado‎: PubMed 25862216

DOI‎: 10.1007/s40268-015-0093-9

https://www.ncbi.nlm.nih.gov/pubmed/25862216 (abre nova janela)

Hemostatic management of severe thrombocytopenia in a patient undergoing pulmonic valve replacement. (abre nova janela)

Tanaka KA, Li P, McHugh SM, Subramaniam K.

Fonte‎: A A Case Rep 2015;5(1):3-5.

Indexado‎: PubMed 26125690

DOI‎: 10.1213/XAA.0000000000000166

https://www.ncbi.nlm.nih.gov/pubmed/26125690 (abre nova janela)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (abre nova janela)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Fonte‎: Anesthesiology 2003;98(6):1513-5.

Indexado‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (abre nova janela)

Recombinant activated factor VII in cardiac surgery: a systematic review. (abre nova janela)

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T.

Fonte‎: Ann Thorac Surg 2007;83(2):707-14.

Indexado‎: PubMed 17258029

DOI‎: 10.1016/j.athoracsur.2006.10.033

https://www.ncbi.nlm.nih.gov/pubmed/17258029 (abre nova janela)

Reduced use of allogeneic platelets through high-yield perioperative autologous plateletpheresis and reinfusion. (abre nova janela)

Alberts M, Bandarenko N, Gaca J, Lockhart E, Milano C, Alexander S, Linder D, Lombard FW, Welsby IJ.

Fonte‎: Transfusion 2014;54(5):1348-57.

Indexado‎: PubMed 24898456

DOI‎: 10.1111/trf.12463

https://www.ncbi.nlm.nih.gov/pubmed/24898456 (abre nova janela)

Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. (abre nova janela)

Arnékian V, Camous J, Fattal S, Rézaiguia-Delclaux S, Nottin R, Stéphan F.

Fonte‎: Interact Cardiovasc Thorac Surg 2012;15(3):382-9.

Indexado‎: PubMed 22623627

DOI‎: 10.1093/icvts/ivs224

https://www.ncbi.nlm.nih.gov/pubmed/22623627 (abre nova janela)

Reducing blood transfusion in aortic surgery: a novel approach. (abre nova janela)

Birla R, Nawaytou O, Shaw M, Jackson A, Mills K, Kuduvalli M, Field M, Agarwal S

Fonte‎: Ann Thorac Surg 2019;108(5):1369-75.

Indexado‎: PubMed 31255616

DOI‎: 10.1016/j.athoracsur.2019.04.127

https://www.ncbi.nlm.nih.gov/pubmed/31255616 (abre nova janela)

Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. (abre nova janela)

Bolliger D, Sreeram G, Duncan A, Molinaro RJ, Szlam F, Chen EP, Tanaka KA.

Fonte‎: Ann Thorac Surg 2009;88(5):1666-8.

Indexado‎: PubMed 19853132

DOI‎: 10.1016/j.athoracsur.2009.03.095

https://www.ncbi.nlm.nih.gov/pubmed/19853132 (abre nova janela)

Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. (abre nova janela)

Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M, Crosta S, Banescu S, Ahmed AB, Beghi C.

Fonte‎: Crit Care 2016;20:5.

Indexado‎: PubMed 26738468

DOI‎: 10.1186/s13054-015-1172-6

https://www.ncbi.nlm.nih.gov/pubmed/26738468 (abre nova janela)

Bloodless orthotopic heart transplantation in a Jehovah's Witness. (abre nova janela)

Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N.

Fonte‎: A A Case Rep 2015;4(10):140-2.

Indexado‎: PubMed 25974419

DOI‎: 10.1213/XAA.0000000000000067

https://www.ncbi.nlm.nih.gov/pubmed/25974419 (abre nova janela)

State of the art - how I manage coagulopathy in cardiac surgery patients. (abre nova janela)

Davidson S.

Fonte‎: Br J Haematol 2014;164(6):779-89.

Indexado‎: PubMed 24450971

DOI‎: 10.1111/bjh.12746

https://www.ncbi.nlm.nih.gov/pubmed/24450971 (abre nova janela)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (abre nova janela)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Fonte‎: Anesthesiology 2011;115(6):1179-91.

Indexado‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (abre nova janela)

Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. (abre nova janela)

Karkouti K, Bartoszko J, Grewal D, Bingley C, Armali C, Carroll J, Hucke HP, Kron A, McCluskey SA, Rao V, Callum J

Fonte‎: JAMA Netw Open 2021;4(4):e213936.

Indexado‎: PubMed 33792729

DOI‎: 10.1001/jamanetworkopen.2021.3936

https://www.ncbi.nlm.nih.gov/pubmed/33792729 (abre nova janela)

Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. (abre nova janela)

Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A.

Fonte‎: Thromb Haemost 2009;102(1):137-44.

Indexado‎: PubMed 19572078

DOI‎: 10.1160/TH08-09-0587

https://www.ncbi.nlm.nih.gov/pubmed/19572078 (abre nova janela)

Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. (abre nova janela)

Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M.

Fonte‎: J Thorac Cardiovasc Surg 2013;145(3 Suppl):S178-85.

Indexado‎: PubMed 23410777

DOI‎: 10.1016/j.jtcvs.2012.12.083

https://www.ncbi.nlm.nih.gov/pubmed/23410777 (abre nova janela)

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. (abre nova janela)

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Fonte‎: Anesthesiology 2013;118(1):40-50.

Indexado‎: PubMed 23249928

DOI‎: 10.1097/ALN.0b013e3182715d4d

https://www.ncbi.nlm.nih.gov/pubmed/23249928 (abre nova janela)

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. (abre nova janela)

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Fonte‎: J Am Heart Assoc 2015;4(6):e002066.

Indexado‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

https://www.ncbi.nlm.nih.gov/pubmed/26037084 (abre nova janela)

Fibrinogen supplementation after cardiac surgery: insights from the zero-plasma trial (ZEPLAST). (abre nova janela)

Ranucci M, Baryshnikova E.

Fonte‎: Br J Anaesth 2016;116(5):618-23.

Indexado‎: PubMed 26893405

DOI‎: 10.1093/bja/aev539

https://www.ncbi.nlm.nih.gov/pubmed/26893405 (abre nova janela)

Bleeding in a Jehovah's Witness patient undergoing a redo aortic valve replacement controlled with cryoprecipitate and a prothrombin complex concentrate. (abre nova janela)

Robblee JA, Wilkes PR, Dickie SJ, Rubens FD, Bormanis J.

Fonte‎: Can J Anaesth 2012;59(3):299-303.

Indexado‎: PubMed 22161243

DOI‎: 10.1007/s12630-011-9647-7

https://www.ncbi.nlm.nih.gov/pubmed/22161243 (abre nova janela)

Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. (abre nova janela)

Roman M, Biancari F, Ahmed AB, Agarwal S, Hadjinikolaou L, Al-Sarraf A, Tsang G, Oo AY, Field M, Santini F, Mariscalco G

Fonte‎: Ann Thorac Surg 2019;107(4):1275-83.

Indexado‎: PubMed 30458156

DOI‎: 10.1016/j.athoracsur.2018.10.013

https://www.ncbi.nlm.nih.gov/pubmed/30458156 (abre nova janela)

Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. (abre nova janela)

Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA.

Fonte‎: Anesth Analg 2007;104(4):763-5.

Indexado‎: PubMed 17377078

DOI‎: 10.1213/01.ane.0000250913.45299.f3

https://www.ncbi.nlm.nih.gov/pubmed/17377078 (abre nova janela)

Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. (abre nova janela)

Solomon C, Schöchl H, Hanke A, Calatzis A, Hagl C, Tanaka K, Rahe-Meyer N.

Fonte‎: Scand J Clin Lab Invest 2012;72(2):121-8.

Indexado‎: PubMed 22233480

DOI‎: 10.3109/00365513.2011.643818

https://www.ncbi.nlm.nih.gov/pubmed/22233480 (abre nova janela)

Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry. (abre nova janela)

Hanke AA, Dellweg C, Kienbaum P, Weber CF, Görlinger K, Rahe-Meyer N.

Fonte‎: Anaesthesia 2010;65(7):688-91.

Indexado‎: PubMed 20477783

DOI‎: 10.1111/j.1365-2044.2010.06367.x

https://www.ncbi.nlm.nih.gov/pubmed/20477783 (abre nova janela)

Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. (abre nova janela)

Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG.

Fonte‎: J Cardiothorac Vasc Anesth 2007;21(6):851-4.

Indexado‎: PubMed 18068065

DOI‎: 10.1053/j.jvca.2007.05.009

https://www.ncbi.nlm.nih.gov/pubmed/18068065 (abre nova janela)

Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. (abre nova janela)

Wademan BH, Galvin SD.

Fonte‎: Interact Cardiovasc Thorac Surg 2014;18(3):360-70.

Indexado‎: PubMed 24263581

DOI‎: 10.1093/icvts/ivt491

https://www.ncbi.nlm.nih.gov/pubmed/24263581 (abre nova janela)

A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. (abre nova janela)

Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jámbor C.

Fonte‎: Anesth Analg 2010;110(3):702-7.

Indexado‎: PubMed 20042444

DOI‎: 10.1213/ANE.0b013e3181c92a5c

https://www.ncbi.nlm.nih.gov/pubmed/20042444 (abre nova janela)

A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. (abre nova janela)

Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH.

Fonte‎: Ann Surg 2010;251(2):217-28.

Indexado‎: PubMed 20010084

DOI‎: 10.1097/SLA.0b013e3181c3bcca

https://www.ncbi.nlm.nih.gov/pubmed/20010084 (abre nova janela)

A review of topical hemostatic agents for use in cardiac surgery. (abre nova janela)

Barnard J, Millner R.

Fonte‎: Ann Thorac Surg 2009;88(4):1377-83.

Indexado‎: PubMed 19766855

DOI‎: 10.1016/j.athoracsur.2009.02.092

https://www.ncbi.nlm.nih.gov/pubmed/19766855 (abre nova janela)

Armentarium of topical hemostatic products in cardiovascular surgery: an update. (abre nova janela)

Forcillo J, Perrault LP.

Fonte‎: Transfus Apher Sci 2014;50(1):26-31.

Indexado‎: PubMed 24412443

DOI‎: 10.1016/j.transci.2013.12.009

https://www.ncbi.nlm.nih.gov/pubmed/24412443 (abre nova janela)

A novel reverse thermosensitive polymer to achieve temporary atraumatic vessel occlusion in infra-popliteal bypasses. (abre nova janela)

Mani K, Campbell A, Fitzpatrick J, Modarai B, Carrell T, Rashid H, Zayed H.

Fonte‎: Eur J Vasc Endovasc Surg 2013;45(1):51-6.

Indexado‎: PubMed 23134676

DOI‎: 10.1016/j.ejvs.2012.10.008

https://www.ncbi.nlm.nih.gov/pubmed/23134676 (abre nova janela)

Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. (abre nova janela)

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N.

Fonte‎: Innovations (Phila) 2012;7(4):229-41.

Indexado‎: PubMed 23123988

DOI‎: 10.1097/IMI.0b013e3182747699

https://www.ncbi.nlm.nih.gov/pubmed/23123988 (abre nova janela)

Control of troublesome bleeding during repair of acute type A dissection with use of modified rapid deployment hemostat (MRDH). (abre nova janela)

Salerno TA, Gaughan C, Suarez M, Panos AL.

Fonte‎: J Card Surg 2009;24(6):722-4.

Indexado‎: PubMed 20078720

DOI‎: 10.1111/j.1540-8191.2009.00915.x

https://www.ncbi.nlm.nih.gov/pubmed/20078720 (abre nova janela)

Topical haemostatic agents. (abre nova janela)

Seyednejad H, Imani M, Jamieson T, Seifalian AM.

Fonte‎: Br J Surg 2008;95(10):1197-225.

Indexado‎: PubMed 18763249

DOI‎: 10.1002/bjs.6357

https://www.ncbi.nlm.nih.gov/pubmed/18763249 (abre nova janela)

An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. (abre nova janela)

Anderson L, Quasim I, Soutar R, Steven M, Macfie A, Korte W.

Fonte‎: Transfus Med 2006;16(1):31-9.

Indexado‎: PubMed 16480437

DOI‎: 10.1111/j.1365-3148.2006.00645.x

https://www.ncbi.nlm.nih.gov/pubmed/16480437 (abre nova janela)

First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (abre nova janela)

Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J.

Fonte‎: Anesthesiology 2011;115(6):1179-91.

Indexado‎: PubMed 21970887

DOI‎: 10.1097/ALN.0b013e31823497dd

https://www.ncbi.nlm.nih.gov/pubmed/21970887 (abre nova janela)

Management of hemorrhage in cardiothoracic surgery. (abre nova janela)

Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA.

Fonte‎: J Cardiothorac Vasc Anesth 2013;27(4 Suppl):S20-34.

Indexado‎: PubMed 23910533

DOI‎: 10.1053/j.jvca.2013.05.014

https://www.ncbi.nlm.nih.gov/pubmed/23910533 (abre nova janela)

Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. (abre nova janela)

Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K.

Fonte‎: Anesthesiology 2012;117(3):531-47.

Indexado‎: PubMed 22914710

DOI‎: 10.1097/ALN.0b013e318264c644

https://www.ncbi.nlm.nih.gov/pubmed/22914710 (abre nova janela)